BR100 Increased By (0.36%)
BR30 Decreased By (-0.13%)
KSE100 Increased By (0.22%)
KSE30 Increased By (0.37%)
AGHA 6.68 Increased By ▲ 0.01 (0.15%)
BECO 4.37 No Change ▼ 0.00 (0%)
BML 57.32 Increased By ▲ 0.88 (1.56%)
BOP 30.35 Increased By ▲ 0.01 (0.03%)
CNERGY 13.12 Increased By ▲ 0.03 (0.23%)
CSIL 5.41 Increased By ▲ 0.05 (0.93%)
FCCL 52.79 Increased By ▲ 0.41 (0.78%)
FFL 14.72 Decreased By ▼ -0.02 (-0.14%)
FNEL 1.12 No Change ▼ 0.00 (0%)
KEL 6.09 No Change ▼ 0.00 (0%)
KOSM 5.73 Increased By ▲ 0.77 (15.52%)
LOTCHEM 26.46 Decreased By ▼ -0.89 (-3.25%)
MLCF 93.16 Increased By ▲ 0.41 (0.44%)
NBP 164.66 Decreased By ▼ -0.32 (-0.19%)
NCPL 55.66 Increased By ▲ 0.02 (0.04%)
NPL 61.16 Decreased By ▼ -0.10 (-0.16%)
OGDC 316.73 Decreased By ▼ -1.03 (-0.32%)
PACE 9.87 Decreased By ▼ -0.06 (-0.6%)
PAEL 35.63 Increased By ▲ 0.13 (0.37%)
PIBTL 14.68 Increased By ▲ 0.11 (0.75%)
PPL 226.91 Decreased By ▼ -0.88 (-0.39%)
PRL 93.02 Increased By ▲ 0.45 (0.49%)
PTC 60.26 Decreased By ▼ -0.37 (-0.61%)
SSGC 23.81 Increased By ▲ 0.01 (0.04%)
TBL 8.75 Increased By ▲ 0.07 (0.81%)
TELE 7.80 Increased By ▲ 0.02 (0.26%)
TPL 22.35 Increased By ▲ 0.12 (0.54%)
TPLP 12.97 Increased By ▲ 0.30 (2.37%)
TREET 22.16 Decreased By ▼ -0.38 (-1.69%)
TRG 56.56 Decreased By ▼ -1.24 (-2.15%)
Markets

Britain's FTSE supported by financials, AstraZeneca

MILAN: UK shares rose on Thursday as financials rallied, tracking strength in their European peers and heavyweight d
Published Updated

MILAN: UK shares rose on Thursday as financials rallied, tracking strength in their European peers and heavyweight drugmaker AstraZeneca was lifted by a strong update.

The FTSE 100 rose 0.3 percent by 0955 GMT, as relief about the U.S. midterm vote delivering no big surprises continued, while the domestically focused mid-cap index rose 0.3 percent.

"With the Dow Jones posting some big gains on Wednesday, the post-US midterm growth rolled over into Thursday," said Connor Campbell, analyst at Spreadex in London.

AstraZeneca rose 2 percent after strong demand for its new drugs -- especially those for cancer -- drove a return to sales growth in the third quarter and the drugmaker said it now anticipated years of sustained improvement.

"This was a decent set of results with the reiteration of guidance largely expected. That said the continued outperformance from the new product launches and core diabetes portfolio should be well received," said Liberum analyst Graham Doyle.

In the same sector, which is seen benefiting from the U.S. vote's outcome, Hikma rallied 6.8 percent after it raised full-year revenue expectations for its key injectables division, as it supplies more opioid painkillers amid a shortage in the United States.

Analysts say a split Congress that is unlikely to significantly cut government healthcare programmes or reduce drug prices in the world's biggest and most profitable market.

Coca-Cola HBC rose 5 percent to the top of the FTSE 100 after the soft drink bottler reported slightly higher-than-expected quarterly revenue growth, driven by higher volumes.

Inmarsat however fell 6.6 percent after trimming its full-year revenues guidance to the lower end of its previous target.

Among other companies reporting results was Britain's No. 2 supermarket Sainsbury, which is seeking is seeking regulatory approval to take over rival Asda.

Its shares rose as much as 1.8 percent after cost savings helped it beat forecasts with a 20 percent increase in first-half profit. They later pared gains and were down 0.5 percent.

Jefferies said the update was largely uneventful and that developments relating to the 7.4 billion-pound Asda takeover were key.

"We believe the market efficiently prices in the possibility of the deal being blocked and that of an approval being granted with fairly extensive store disposal requirements," they said.

Financials provided the biggest boost to the FTSE, with shares in Lloyds, HSBC and Royal Bank of Scotland all rising more than 1 percent as the broader European banking sector rose on the back of strong results.

Among top fallers was Marks & Spencer after HSBC cut its price target on the stock.

Copyright Reuters, 2018
 

Comments

Comments are closed for this article.